ClinicalTrials.gg
CompletedNCT01764516Updated Jan 9, 2013

Study on Serum Zinc and Selenium Levels in Epileptic Patients

An observational study in Generalized Epileptic, sponsored by Arak University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-09.

Sponsored by Arak University of Medical Sciences · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study was carried out with the purpose of evaluating zinc and selenium levels in serum of epileptic patients and compare with normal individuals.

Read the detailed description

Forty patients aged 18 to 50 years visiting Vali-Asr hospital in Arak, I.R. Iran, who were diagnosed with generalized form of epilepsy by a neurologist for the first time were recruited as cases. The control group (n=40) was selected from healthy individuals, in whom no disease was diagnosed until this study, and were matched to the case group by age, sex, and economical status.

02

Conditions studied

  • Generalized Epileptic

Keywords

  • zinc
  • selenium
  • serum
  • epilepsy
  • antioxidants
03

In context

Epilepsy, Generalized

39 studies on the registry are indexed under Epilepsy, Generalized; 4 are open to participants now.

This study's enrollment of 40 is below the median of 80 across 13 observational studies indexed under Epilepsy, Generalized.

Browse Epilepsy, Generalized studies →

Lead sponsor

Arak University of Medical Sciences is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

all generalized and single epileptic patiants which were identify for fist time

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

New generalized and single epileptic cases patients who accept and sign the approval form of ethical committee non smoker, no trauma, no use of selenium supplement, no use of zinc supplement, no use of vitamin A supplement, no use of vitamin D supplement, no Weight loss, no Diarrhea, no addiction, no alcohol consumption, no use of certain medications,

Exclusion criteria

Exclusion Criteria:

presence of above criteria as well as, generalized and single epileptic cases under treatment

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
40 participants (actual)
Target follow-up
1 Week
Patient registry
Yes
Biospecimen retention
None retained

Groups and cohorts

  • Zinc level (micro gram per deciliter)

    In all cases

  • Selenium level (micro gram per deciliter)

    In all cases

  • Zinc level in male (micro gram per deciliter)
  • Selenium level in male (micro gram per deciliter)
  • Zinc level in Female (micro gram per decilitre)
  • Selenium level in Female (micro gram per decilitre)
06

What researchers measure

Primary outcomes

  1. Study on Serum Zinc and Selenium Levels in Epileptic Patients

    decrement in serum zinc and selenium level

    Time frame: 5 months

Secondary outcomes

  1. Comparison between the selenium levels by gender in two groups

    Time frame: 5 months

07

Study locations

1 site
  • Vali-Asr Hospital
    Arak, Central province, Iran, Islamic Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Mar 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2013
First posted
Jan 9, 2013
Start
Nov 2011
Primary completionActual
Mar 2012
CompletionActual
May 2012
Last update
Jan 9, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01764516
Lead sponsor
Arak University of Medical Sciences
Responsible party
Dr. Farahani Heidar (faculity of medicine, department of biochemistry, Arak University of Medical Sciences) — Principal investigator
First posted
Jan 9, 2013
Start date
Nov 2011
Primary completion
Mar 2012
Completion
May 2012
Last update
Jan 9, 2013

Study contacts

Heidar N Farahani, PhD
principal investigator · Department of Biochemistry,Arak medical sciences university

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion